GlassScriptPhysician profile
Melanie Jones
NPI 1548842453
$5,090.16
in general payments reported to CMS, 2019-2025
37 companies · $458 in 2025
The $458 reported for 2025 was more than what 75% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $754 · 2022: $2,249 · 2023: $1,524 · 2024: $105 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,104.14 | 2021-2025 | |
| Lilly USA, LLC | $559.78 | 2021-2025 | Reyvow, Emgality, Zepbound |
| Ucb, INC. | $341.31 | 2021-2023 | Briviact |
| Astrazeneca Pharmaceuticals LP | $253.06 | 2025 | Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.34 | 2021-2024 | Trulance |
| Inspire Medical Systems, INC. | $227.14 | 2022-2023 | Inspire |
| Harmony Biosciences LLC | $213.73 | 2022-2023 | Wakix |
| Pfizer INC. | $183.89 | 2023 | |
| Biogen, INC. | $183.50 | 2021-2023 | Vumerity |
| Novartis Pharmaceuticals Corporation | $158.36 | 2021-2023 | |
| Argenx US, INC. | $132.27 | 2022-2023 | Vyvgart, Vyvgart Hytrulo |
| Jazz Pharmaceuticals INC. | $125.98 | 2021-2023 | |
| Sk Life Science, INC. | $110.23 | 2021-2023 | |
| Genzyme Corporation | $108.27 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $107.90 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $94.77 | 2021-2023 | Ultomiris |
| Emd Serono, INC. | $94.31 | 2021-2022 | |
| Neurelis, INC. | $93.35 | 2021-2022 | |
| Horizon Therapeutics Plc | $91.16 | 2022-2023 | Uplizna |
| Amgen INC. | $82.00 | 2021-2022 | |
| Lundbeck LLC | $81.92 | 2021-2024 | Vyepti |
| Csl Behring | $70.77 | 2021-2023 | Hizentra |
| Upsher-Smith Laboratories LLC | $56.97 | 2021-2022 | |
| Tanabe Pharma America, INC. | $48.65 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $40.67 | 2022 | |
| Idorsia Pharmaceuticals US INC | $34.03 | 2023 | Quviviq |
| Acorda Therapeutics, INC | $29.71 | 2023 | Inbrija |
| Takeda Pharmaceuticals U.S.A., INC. | $29.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $27.95 | 2022 | |
| Merz Pharmaceuticals, LLC | $27.80 | 2023 | Xeomin |
| Ge Healthcare | $25.46 | 2023 | |
| Vanda Pharmaceuticals INC. | $24.25 | 2021 | |
| Acadia Pharmaceuticals INC | $20.93 | 2022 | |
| Genentech USA, INC. | $19.31 | 2023 | Ocrevus |
| Kyowa Kirin, INC. | $17.49 | 2022 | |
| Averitas Pharma INC. | $15.48 | 2023 | Qutenza |
| Currax Pharmaceuticals LLC | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.